Table 2. Characteristics of Patients Administered Rituximab With or Without Confirmed Progression.
| Characteristica | Rituximab With Confirmed Progression | Rituximab Without Confirmed Progression | P Valueb |
|---|---|---|---|
| Categorical | |||
| No. of patients | 12 | 42 | |
| Female, No. (%) | 7 (58) | 25 (60) | >.99 |
| Reason for rituximab, No. (%) | |||
| Progression | 11 (92) | 26 (62) | .16 |
| Relapses | 1 (8) | 3 (7) | |
| Progression and relapses | 0 | 3 (7) | |
| Other | 0 | 0 (24) | |
| Relapses under treatment, No. (%) | 1 (8) | 5 (12) | >.99 |
| Continuous | |||
| No. of patients | 12 | 42 | |
| Age, y | |||
| Mean (SD) | 49.7 (10.6) | 48.8 (9.4) | .95 |
| Median (range) | 48.0 (33.0-71.0) | 49.0 (23.0-70.0) | |
| Disease duration, y | |||
| Mean (SD) | 19.0 (10.6) | 18.6 (9.0) | .83 |
| Median (range) | 19.5 (3.0-40.0) | 18.0 (3.0-39.0) | |
| Rituximab, No. of cycles | |||
| Mean (SD) | 6.00 (2.09) | 4.29 (2.99) | .04 |
| Median (range) | 6.50 (3.0-9.00) | 3.50 (1.00-11.00) | |
| Rituximab, cumulative dose, mg | |||
| Mean (SD) | 9.54 (3.86) | 6.00 (3.85) | .007 |
| Median (range) | 8.50 (5.00-15.00) | 5.00 (1.00-16.00) | |
| Rituximab, treatment duration, mo | |||
| Mean (SD) | 60.9 (27.2) | 42.1 (30.7) | .03 |
| Median (range) | 49.5 (32.0-110.0) | 34.5 (6.0-107.0) | |
| Rituximab, treatment intensity, mg/moc | |||
| Mean (SD) | 161.03 (32.10) | 160.32 (50.85) | .88 |
| Median (range) | 156.05 (131.82-250.00) | 160.26 (67.31-333.33) | |
| Ordinal | |||
| EDSS BL | |||
| Mean (SD) | 5.71 (1.41) | 6.11 (1.30) | .35 |
| Median (range) | 6.00 (3.00-7.50) | 6.50 (2.50-8.50) |
Abbreviation: EDSS BL, Expanded Disability Status Scale score after baseline.
a
Number and percentage of patients with measurements are given for categorical variables; mean (SD) and median (range) are given for continuous variables.
b
Derived from Fisher exact tests (categorical) and from Wilcoxon rank sum tests (Mann-Whitney tests, continuous).
c
Defined as the total dose in milligrams of rituximab administered divided by the duration of treatment in months.